North America Intracranial Aneurysm Market Report and Forecast 2024-2032

North America Intracranial Aneurysm Market Outlook

The North America intracranial aneurysm market size is expected to grow at a CAGR of 21.07% during the forecast period of 2024-2032, driven by the growing prevalence of intracranial aneurysms and the rise in technological innovations in treatment devices in the region. 

Key Takeaways

• Around 6.8 million people have an unruptured intracranial aneurysm in the United States, with the rate of rupture estimated to be 8-10 per every 100,000 individuals annually. This rising prevalence is expected to impact market demand.

• The development of new treatment options with higher success rates and better safety profiles is likely to augment the North America intracranial aneurysm market share in coming years. In December 2023, Galaxy Therapeutics’ Endovascular Aneurysm Lattice (SEAL) embolization system, showed a 100% technical success rate, 76.9% rate of progressive complete occlusion, and 0% retreatment rate in the PRE-SEAL IT trial.

• In May 2023, Stryker Corporation completed the acquisition of Cerus Endovascular Ltd., gaining access to Cerus Endovascular's Contour Neurovascular System and Neqstent Coil Assisted Flow Diverter, thereby strengthening its existing portfolio of aneurysm treatment solutions. Such strategic partnerships are expected to elevate market value in the region.

North America Intracranial Aneurysm Market Analysis

Intracranial aneurysm, also known as brain aneurysm or cerebral aneurysm is a condition characterized by ballooning or bulging in a blood vessel in the brain. Rupturing or leaking of the aneurysm can cause bleeding in the brain called hemorrhagic stroke. A ruptured aneurysm can be life-threatening and requires immediate treatment. Advancements in endovascular techniques, including improvements in device technology and materials used for endovascular coiling and flow diversion are expected to significantly impact North America intracranial aneurysm market demand. In addition, the rising patient inclination towards minimally invasive procedures owing to the associated benefits such as fewer complications and reduced recovery time are poised to influence the market dynamics.

The market is experiencing a surge in the demand for intracranial aneurysm treatments which can be attributed to the increased prevalence of the condition in North America. Recent data suggests that around 6.8 million people have an unruptured intracranial aneurysm in the United States, with the rate of rupture estimated to be 8-10 per every 100,000 individuals annually. With around 30,000 people suffering from an intracranial aneurysm rupture every year in the region, the market size is likely to expand in the coming years.

The key players in the market are actively investing in developing new treatment options for intracranial aneurysms with higher success rates and better safety profiles, thereby contributing to the North America intracranial aneurysm market growth. In December 2023, data revealed at the Barts Research and Advanced Interventional Neuroradiology (BRAIN) conference demonstrated positive results for a device abelled “the third way” developed by Galaxy Therapeutics (a United States-based, clinical-stage medical device company). It is developed to treat intracranial aneurysms using an intrasaccular approach. The one-year results of a first-in-human study, the PRE-SEAL IT trial which evaluated the efficacy of the novel Saccular Endovascular Aneurysm Lattice (SEAL) embolization system, showed a 100% technical success rate, 76.9% rate of progressive complete occlusion at 1 year and 0% retreatment rate. Thus, the SEAL device exhibited effectiveness as well as a good safety profile across a range of challenging aneurysms. The development of such innovative devices is anticipated to propel the market growth in the forecast period.

One of the significant North America intracranial aneurysm market trends is the increased merger and acquisition initiatives among the leading market players. In May 2023, Stryker Corporation completed the acquisition of Cerus Endovascular Ltd., a United States-based medical technology company specializing in interventional neuroradiology devices for the treatment of intracranial aneurysms. Under this acquisition, the company will get access to Cerus Endovascular's CE Marked products, the Contour Neurovascular System as well as the Neqstent Coil Assisted Flow Diverter, strengthening Stryker’s existing portfolio of aneurysm treatment solutions. Such strategic partnerships are expected to foster better access to intracranial aneurysm treatments and are expected to elevate market value in the region.

North America Intracranial Aneurysm Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Intracranial Aneurysm Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Stryker

• B. Braun Melsungen AG

• MicroPort Scientific Corporation

• Medtronic

• Johnson & Johnson

• Codman Neuro (Integra Lifesciences)

• Raumedic AG

• Delta Surgical

• Penumbra, Inc.

• Mizuho Medical Co. Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report